Ekaterina Loskutova

phone: c/o +353 1402 2841
email: losk.katerina@gmail.com


Development of a Novel Adjunct Therapy for the Management of Glaucoma

Glaucoma, which is a progressive optic neuropathy, is the second leading cause of global blindness. In glaucoma, as the retinal nerve cells die, the connection between the eye and the brain is gradually diminished. Current therapeutic options are limited, and typically fail to arrest disease progression for the majority of glaucoma patients.

Recent evidence indicates that three dietary carotenoids which accumulate in the retina (lutein, zeaxanthin and meso-zeaxanthin) may be involved in glaucoma pathogenesis. These carotenoid levels are low in glaucoma subjects, and the lack thereof is associated with more severe visual loss and structural damage particularly affecting central vision.

This study is a randomised, placebo controlled and double masked clinical trial designed to investigate the effects of dietary macular carotenoids supplementation on disease progression, visual function and quality of life in glaucoma patients. This study will ultimately determine, for the first time, whether macular carotenoid enrichment can provide an effective adjunct therapy that alters disease progression and quality-of-life impact of glaucoma in affected individuals



Back to Top

     Find us on Facebook      Follow us on Twitter      Follow us on LinkedIn

Member of the European University Association